ST2L: Key Regulator of Cell Surface and Signaling Pathways (G9173)

ST2L: Key Regulator of Cell Surface and Signaling Pathways

The 7-transmembrane protein ST2L (secretory transtranslocation of nucleotides) is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and immune cells. It is a key regulator of the cell surface, playing a role in the production and distribution of proteins and other molecules across the membrane. In addition, ST2L is also known to be a potential drug target and biomarker.

The ST2L protein is composed of 7 transmembrane alpha helical subunits that are held together by a disulfide bond. The protein has a length of approximately 400 amino acids and a calculated molecular mass of 43 kDa. ST2L is expressed in various tissues and cells of the human body , including the epithelial layer of the skin, the endothelial layer of the blood vessels, and the immune cells such as T and B cells.

One of the unique features of ST2L is its ability to regulate the production and distribution of proteins across the cell membrane. This is accomplished through the use of the ST2L protein, which is involved in the secretory transtranslocation of nucleotides. This process allows ST2L to regulate the production of proteins in the cytoplasm and to transport them to the cell surface for release into the intercellular space.

In addition to its role in protein regulation, ST2L is also known to be involved in the regulation of cell signaling pathways. For example, ST2L has been shown to be involved in the regulation of T cell receptor (TCR) signaling, which is critical for the development and activation of T cells. In addition, ST2L has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed.

Given its involvement in a variety of cellular processes, ST2L has attracted significant interest as a potential drug target and biomarker. Studies have shown that ST2L can be targeted by small molecules such as inhibitors, which can inhibit the activity of ST2L and its downstream signaling pathways . Additionally, ST2L has also been shown to be involved in the regulation of cellular signaling pathways, which makes it an attractive signaling target for small molecules that can modulate cellular signaling pathways.

In conclusion, ST2L is a 7-transmembrane protein that is expressed in various tissues and cells of the human body. It plays a key role in the regulation of protein production and distribution, as well as the regulation of cell signaling pathways. As a result , ST2L has attracted significant interest as a potential drug target and biomarker. Further research is needed to fully understand the role of ST2L in cellular signaling pathways and its potential as a drug.

Protein Name: Interleukin 1 Receptor Like 1

Functions: Receptor for interleukin-33 (IL-33); signaling requires association of the coreceptor IL1RAP. Its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. Possibly involved in helper T-cell function (PubMed:16286016) (Probable). Upon tissue injury, induces UCP2-dependent mitochondrial rewiring that attenuates the generation of reactive oxygen species and preserves the integrity of Krebs cycle required for persistent production of itaconate and subsequent GATA3-dependent differentiation of inflammation-resolving alternatively activated macrophages (By similarity)

The "IL1RL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL1RL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA | INCA1 | INCENP | INE1 | INE2 | INF2 | ING1 | ING2 | ING2-DT | ING3